Educational only — not medical advice. If you’re in crisis or thinking about suicide: call or text 988 (U.S.) or your local emergency number. Support resources. Under construction and review—see the updates log.
Brand: Requip
Published 2025-12-23 · Last reviewed 2025-12-30 · 4 references
Content sourced from FDA labeling (DailyMed) and peer-reviewed literature.
Ropinirole (brand Requip) is a non-ergoline dopamine agonist indicated for Parkinson’s disease and moderate-to-severe primary RLS (label).
In RLS, dopamine agonists can improve symptoms but require long-term risk management. A key concern is augmentation, which shapes follow-up plans and influences drug selection frameworks (guideline/clinical).
Clinically important adverse effects include somnolence/sudden sleep onset, orthostatic hypotension, hallucinations/psychosis, and impulse-control symptoms; these risks can be especially relevant in serious mental illness (label/clinical).
Ropinirole is metabolized primarily by CYP1A2, so interaction review includes CYP1A2 inhibitors/inducers and smoking status (label/clinical).
The ropinirole compare view, evidence feed, and print page support side-by-side review of RLS options and monitoring topics.
In RLS, ropinirole can be effective but is usually paired with explicit monitoring for augmentation and neuropsychiatric adverse effects. In patients with mood or psychotic disorders, dopaminergic activation risks can be clinically limiting and may shift preference toward non-dopaminergic strategies (guideline/clinical).
View labelExactRefer to the Glossary entry on Neurotransmitters for background on receptor systems involved in serious mental illness.
Dopamine agonist activity with relative D2/D3 receptor affinity (label/class).
Dopaminergic therapies can precipitate or worsen hallucinations, impulsivity, and mood destabilization in vulnerable patients, which is relevant in serious mental illness (label/clinical).